OHSU

IRB #

IRB00009622

Title

A Phase 1, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients with Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

To study the safety and tolerability of CDX-1127 (study drug) in people with solid tumors and hematologic (blood) cancers

Medical Condition(s)

1.) B cell hematologic malignancies known to express CD27 (chronic lymphocytic leukemia, Burkett's lymphoma, mantle cell lymphoma, primary lymphoma of the central nervous system, and marginal zone B cell lymphoma)
2.) Renal (clear) cell carcinoma

Eligibility Criteria

1. Male or female age 18 years or older.
2. Diagnosis of one of the cancers listed above.
3. Cancer must be recurrent or treatment refractory with no remaining approved therapy options.
4. Life expectancy of 12 weeks or longer.
5. Additional eligibility criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 3 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Celldex Therapeutics, Inc.

Recruitment End

05/30/2014

Compensation Provided

No


Go Back